Abzena’s AGM update highlights continued strong progress since the interim stage, with the recent US acquisitions (now integrated under the Abzena brand) driving strong growth in cell line and bio-conjugation revenue. In addition, the clinical-stage Abzena inside portfolio has expanded to 12 programmes. Several of these are making strong progress towards commercialisation with leading partners, notably GS-5745 (partnered with Gilead Sciences) in gastric cancer for which interim Phase III data is ....
